In this webinar, Dr. Mathias Droescher, senior scientist at AbbVie Deutschland GmbH & Co. KG will explore how advanced technologies such as Ella, to improve the sensitivity and throughput of sample analysis in preclinical as well as early-phase clinical projects.
Attend this webinar to discover:
- Relevance of high-throughput LBA platforms for routine analysis
- Direct transfer of traditional ELISA's to Simple Plex
- Evaluation of the home-brew applications (DIG cartridges)
- Routine application of the NF-L cartridge for plasma applications
AbbVie Deutschland GmbH & Co. KG
Mathias Droescher is a Senior Scientist at AbbVie Germany, focusing on Biomarker Discovery in Neuroscience. He is responsible for the ultra-sensitive immunoassay development in the Molecular and Imaging Biomarker group and in general works on the identification as well as the implementation of translatable biomarkers into preclinical research. In this regard, he explores ways in which biomarkers can be exploited in terms of target engagement, monitoring disease progression and how they are linked to functional or pathophysiological readouts. A major challenge in Neuroscience still constitutes the limitation of available sample volumes, the low abundance of potential biomarkers as well as minor differences between control and disease groups. Thus, the group strives to implement the high need of advanced technologies to improve the sensitivity and throughput of sample analysis in preclinical as well as early-phase clinical projects.